Sierra Oncology, Inc. SRRA
We take great care to ensure that the data presented and summarized in this overview for Sierra Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SRRA
Top Purchases
Top Sells
About SRRA
Insider Transactions at SRRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2022
|
Stephen George Dilly CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
$275,000
$55.0 P/Share
|
|
Jul 01
2022
|
Craig A Collard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,500
-100.0%
|
$742,500
$55.0 P/Share
|
|
Jul 01
2022
|
Andrew R Allen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,650
-100.0%
|
$90,750
$55.0 P/Share
|
|
Jul 01
2022
|
Barbara Klencke Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
$275,000
$55.0 P/Share
|
|
Jul 01
2022
|
Barbara Klencke Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
$550,000
$55.0 P/Share
|
|
Jul 01
2022
|
Andrew Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,314,127
-100.0%
|
$72,276,985
$55.0 P/Share
|
|
Jul 01
2022
|
Gaurav Aggarwal Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,735,853
-100.0%
|
$150,471,915
$55.0 P/Share
|
|
Jul 01
2022
|
Mona Ashiya Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,964,770
-100.0%
|
$108,062,350
$55.0 P/Share
|
|
Jul 01
2022
|
Vivo Opportunity, LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,329,512
-100.0%
|
$183,123,160
$55.0 P/Share
|
|
Jul 01
2022
|
Orbimed Advisors LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,964,770
-100.0%
|
$108,062,350
$55.0 P/Share
|
|
Apr 27
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
16,030
+29.74%
|
-
|
|
Apr 27
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,139,771
-100.0%
|
-
|
|
Apr 06
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
6,347
-100.0%
|
$234,839
$37.25 P/Share
|
|
Apr 06
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,347
+50.0%
|
$76,164
$12.05 P/Share
|
|
Apr 05
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,700
$37.09 P/Share
|
|
Apr 05
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,200
$12.05 P/Share
|
|
Apr 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$70,000
$35.14 P/Share
|
|
Apr 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,700
$37.05 P/Share
|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,200
$12.05 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders